14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
IART vs KIDS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Integra LifeSciences Holdings (IART) is the stronger overall head-to-head candidate over OrthoPediatrics Corp. (KIDS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IART carries a Unified Composite Score of 48.5/100 (HOLD) at $13.55 (5.7x Forward P/E, 9.9% operating margin), whereas KIDS carries 45.1/100 (HOLD) at $32.51 (N/M Forward P/E, -8.2% operating margin).
Growth vs. Quality Trade-Off: IART earns the overall head-to-head edge with a stronger Unified Composite Score (48.5/100 HOLD vs. KIDS 45.1/100 HOLD) and 1.57β · 61% Vol risk profile, whereas KIDS leads top-line expansion (+18.6% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: IART is currently in a Breakdown options structure phase (RSI 47.3); meanwhile KIDS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 64.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IART vs KIDS. Trailing 12-month operating profitability (IART 9.9% vs KIDS -8.2%) and valuation multiples (IART 5.7x vs KIDS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $850.2M market capitalization and -8.2% operating margin.
OpEx & R&D Reinvestment82.0% of Rev ($217M)
90D Engineering Disclosures0 Published
Investor FAQ IART vs KIDS Key Questions & Quantitative Answers
As of Nov 19, 2026, Integra LifeSciences Holdings (IART) is the stronger overall head-to-head candidate over OrthoPediatrics Corp. (KIDS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IART carries a Unified Composite Score of 48.5/100 (HOLD) at $13.55 (5.7x Forward P/E, 9.9% operating margin), whereas KIDS carries 45.1/100 (HOLD) at $32.51 (N/M Forward P/E, -8.2% operating margin). Growth vs. Quality Trade-Off: IART earns the overall head-to-head edge with a stronger Unified Composite Score (48.5/100 HOLD vs. KIDS 45.1/100 HOLD) and 1.57β · 61% Vol risk profile, whereas KIDS leads top-line expansion (+18.6% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: IART is currently in a Breakdown options structure phase (RSI 47.3); meanwhile KIDS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 64.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IART leads the Growth & Scale pillar: IART posts +2.3% YoY revenue growth and +0.4% YoY earnings growth on $1.66B TTM revenue (55.5% gross margin, 9.9% operating margin), compared with KIDS at +18.6% YoY revenue growth and +0.0% YoY earnings growth on $264M TTM revenue (73.8% gross margin, -8.2% operating margin). On trailing 12-month operating scale, IART generates $1.66B in USD-normalized revenue versus $264M for KIDS. In operating R&D and SG&A reinvestment, IART deploys 45.6% of Rev ($755M) (0 90-day corporate R&D disclosures) versus 82.0% of Rev ($217M) (0 disclosures) for KIDS.
IART screens cheaper on headline valuation multiples. IART trades at 5.7x Forward P/E, 81.5x Trailing P/E, 0.71x PEG, and 0.6x EV/Revenue (4.3% FCF margin), whereas KIDS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.2x EV/Revenue (0.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IART (1.2% ROE) versus KIDS (-9.8% ROE) capital efficiency.
In options market volatility and institutional positioning, IART carries 57.4% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.92x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.57β · 61% Vol realized risk). By comparison, KIDS carries 145.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 108% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.